Sang Y Kang

Array ( [id] => 18986498 [patent_doc_number] => 20240058467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/349337 [patent_app_country] => US [patent_app_date] => 2023-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 128025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18349337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18523024 [patent_doc_number] => 20230233678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => DENDRITIC CELL TUMOR VACCINE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/169174 [patent_app_country] => US [patent_app_date] => 2023-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18169174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18529998 [patent_doc_number] => 20230235066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => GLYCOME FACTORS DRIVING MELANOMA PROGRESSION [patent_app_type] => utility [patent_app_number] => 18/101285 [patent_app_country] => US [patent_app_date] => 2023-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18101285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18829704 [patent_doc_number] => 20230398228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/062996 [patent_app_country] => US [patent_app_date] => 2022-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18467085 [patent_doc_number] => 20230201366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => ANTI-PSMA CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/056080 [patent_app_country] => US [patent_app_date] => 2022-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056080 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18707663 [patent_doc_number] => 20230330242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => IMMUNOCONJUGATES AND METHODS [patent_app_type] => utility [patent_app_number] => 17/936346 [patent_app_country] => US [patent_app_date] => 2022-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17936346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18165461 [patent_doc_number] => 20230032060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS [patent_app_type] => utility [patent_app_number] => 17/823492 [patent_app_country] => US [patent_app_date] => 2022-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18278416 [patent_doc_number] => 20230093888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS [patent_app_type] => utility [patent_app_number] => 17/823494 [patent_app_country] => US [patent_app_date] => 2022-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18324913 [patent_doc_number] => 20230123041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => IMMUNOCONJUGATES AND METHODS [patent_app_type] => utility [patent_app_number] => 17/812869 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17944426 [patent_doc_number] => 20220331443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/851340 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 195 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18196519 [patent_doc_number] => 20230050038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => PDGF MUTANTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/836684 [patent_app_country] => US [patent_app_date] => 2022-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8794 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308720 [patent_doc_number] => 20230112620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA [patent_app_type] => utility [patent_app_number] => 17/831085 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18245981 [patent_doc_number] => 11602544 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Compositions and methods for treating EGFR positive cancers [patent_app_type] => utility [patent_app_number] => 17/663758 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 40 [patent_no_of_words] => 62446 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17663758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830135 [patent_doc_number] => 20220267439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => Methods for Manipulating Phagocytosis Mediated by CD47 [patent_app_type] => utility [patent_app_number] => 17/736896 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058971 [patent_doc_number] => 11938164 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Exosome-based cancer assays [patent_app_type] => utility [patent_app_number] => 17/714295 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 40 [patent_no_of_words] => 58598 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945765 [patent_doc_number] => 20220332782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => Combined Artificial Cell Death/Reporter System Polypeptide for Chimeric Antigen Receptor Cell and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/657803 [patent_app_country] => US [patent_app_date] => 2022-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533692 [patent_doc_number] => 20220112301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA [patent_app_type] => utility [patent_app_number] => 17/560006 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18085561 [patent_doc_number] => 11535679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma [patent_app_type] => utility [patent_app_number] => 17/558404 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 30348 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17558404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18869857 [patent_doc_number] => 11857637 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Anti-CD25 antibody-maytansine conjugates and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/519183 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 14 [patent_no_of_words] => 35282 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 355 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18230728 [patent_doc_number] => 20230069722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/356497 [patent_app_country] => US [patent_app_date] => 2021-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356497 [rel_patent_id] =>[rel_patent_doc_number] =>)